REDWOOD CITY, Calif., June 4, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. ("AcelRx") (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced today that Richard King, President and Chief Executive Officer of AcelRx, will present at the Jefferies 2012 Global Healthcare Conference in New York. The presentation is scheduled for Thursday, June 7, 2012 at 3:30 p.m. ET/ 12:30 p.m. PT.
The presentation will be webcast live and can be accessed through the following link: http://wsw.com/webcast/jeff68/acrx/.
For those not able to listen to the live broadcast, an archive of the presentation will be available through www.acelrx.com.
About AcelRx PharmaceuticalsAcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is currently in Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain, and AcelRx plans to initiate a Phase 2 study funded by a grant from USAMRMC, contingent on approval of the proposed clinical protocol for the study by USAMRMC. For additional information about AcelRx's innovative programs please visit www.acelrx.com. Forward-Looking Statements